上海醫藥(02607.HK)公布，下屬全資子公司上藥東英(江蘇)藥業的注射用帕瑞昔布鈉收到國家藥監局頒發的《藥品補充申請批准通知書》，該藥品新增規格40mg獲得批准。注射用帕瑞昔布鈉主要用於手術後疼痛的短期治療，最早由輝瑞研發，於2002年在歐洲上市。
上海醫藥(02607.HK)：注射用帕瑞昔布鈉新增規格獲內地批准
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.